Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Research & Development (2020 - 2025)

Barinthus Biotherapeutics' Research & Development history spans 6 years, with the latest figure at $3.9 million for Q4 2025.

  • For Q4 2025, Research & Development fell 52.7% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $25.6 million, down 39.47%, while the annual FY2025 figure was $25.6 million, 39.47% down from the prior year.
  • Research & Development reached $3.9 million in Q4 2025 per BRNS's latest filing, down from $5.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $15.1 million in Q3 2023 to a low of $3.9 million in Q4 2025.
  • Average Research & Development over 5 years is $8.8 million, with a median of $9.0 million recorded in 2022.
  • Peak YoY movement for Research & Development: skyrocketed 168.16% in 2021, then tumbled 52.7% in 2025.
  • A 5-year view of Research & Development shows it stood at $6.9 million in 2021, then surged by 77.08% to $12.2 million in 2022, then plummeted by 47.7% to $6.4 million in 2023, then skyrocketed by 30.39% to $8.3 million in 2024, then crashed by 52.7% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Research & Development are $3.9 million (Q4 2025), $5.4 million (Q3 2025), and $8.0 million (Q2 2025).